Listed

Armata Pharmaceuticals, Inc.

ARMPNYSECIK 921114HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$10.3m, Q2 FY2026
Net income$74.1m, Q2 FY2026
Armata Pharmaceuticals, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Operating income$m(10.3)Operating income, Q3 FY2023, three months to 2023-09-30−$10.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-13, accession 0001558370-24-015530.Report this figure(9.6)Operating income, Q4 FY2023, three months to 2023-12-31−$9.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-21, accession 0001558370-25-003406. Derived: 12-month figure less the 9-month figure.Report this figure(10.2)Operating income, Q1 FY2024, three months to 2024-03-31−$10.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-14, accession 0001558370-25-007765.Report this figure(11.9)Operating income, Q2 FY2024, three months to 2024-06-30−$11.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-12, accession 0001558370-25-011235.Report this figure(9.8)Operating income, Q3 FY2024, three months to 2024-09-30−$9.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001104659-25-110383.Report this figure(10.5)Operating income, Q4 FY2024, three months to 2024-12-31−$10.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-25, accession 0001104659-26-034532. Derived: 12-month figure less the 9-month figure.Report this figure(8.2)Operating income, Q1 FY2025, three months to 2025-03-31−$8.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001104659-26-060333.Report this figure(6.8)Operating income, Q2 FY2025, three months to 2025-06-30−$6.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-12, accession 0001104659-26-094907.Report this figure(7.8)Operating income, Q3 FY2025, three months to 2025-09-30−$7.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001104659-25-110383.Report this figure(13.8)Operating income, Q4 FY2025, three months to 2025-12-31−$13.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-25, accession 0001104659-26-034532. Derived: 12-month figure less the 9-month figure.Report this figure(8.8)Operating income, Q1 FY2026, three months to 2026-03-31−$8.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001104659-26-060333.Report this figure(10.3)Operating income, Q2 FY2026, three months to 2026-06-30−$10.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-12, accession 0001104659-26-094907.Report this figure
Interest expense$m1.2Interest expense, Q3 FY2023, three months to 2023-09-30$1.2m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2023-11-14, accession 0001558370-23-019036.Report this figurenot reported1.8Interest expense, Q1 FY2024, three months to 2024-03-31$1.8m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-05-07, accession 0001558370-24-007068.Report this figure2.7Interest expense, Q2 FY2024, three months to 2024-06-30$2.7m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-08-13, accession 0001558370-24-012061.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Income tax$m0.0Income tax, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-13, accession 0001558370-24-015530.Report this figurenot reported0.0Income tax, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-12, accession 0001558370-25-011235.Report this figure0.0Income tax, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-08-13, accession 0001558370-24-012061.Report this figure0.0Income tax, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-12, accession 0001104659-25-110383.Report this figurenot reported0.0Income tax, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-13, accession 0001104659-26-060333.Report this figure0.0Income tax, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-12, accession 0001104659-26-094907. Derived: 6-month figure less the 3-month figure.Report this figure0.0Income tax, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-12, accession 0001104659-25-110383.Report this figurenot reported0.0Income tax, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-13, accession 0001104659-26-060333.Report this figure0.0Income tax, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-12, accession 0001104659-26-094907. Derived: 6-month figure less the 3-month figure.Report this figure
Net income$m(31.2)Net income, Q3 FY2023, three months to 2023-09-30−$31.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-13, accession 0001558370-24-015530.Report this figure(19.8)Net income, Q4 FY2023, three months to 2023-12-31−$19.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-21, accession 0001558370-25-003406. Derived: 12-month figure less the 9-month figure.Report this figure(25.0)Net income, Q1 FY2024, three months to 2024-03-31−$25.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-14, accession 0001558370-25-007765.Report this figure9.0Net income, Q2 FY2024, three months to 2024-06-30$9.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-12, accession 0001558370-25-011235.Report this figure(5.5)Net income, Q3 FY2024, three months to 2024-09-30−$5.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001104659-25-110383.Report this figure2.6Net income, Q4 FY2024, three months to 2024-12-31$2.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-25, accession 0001104659-26-034532. Derived: 12-month figure less the 9-month figure.Report this figure(6.5)Net income, Q1 FY2025, three months to 2025-03-31−$6.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-13, accession 0001104659-26-060333.Report this figure(16.3)Net income, Q2 FY2025, three months to 2025-06-30−$16.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001104659-26-094907.Report this figure(26.7)Net income, Q3 FY2025, three months to 2025-09-30−$26.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001104659-25-110383.Report this figure(124)Net income, Q4 FY2025, three months to 2025-12-31−$124.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-25, accession 0001104659-26-034532. Derived: 12-month figure less the 9-month figure.Report this figure(115)Net income, Q1 FY2026, three months to 2026-03-31−$115.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-13, accession 0001104659-26-060333.Report this figure74.1Net income, Q2 FY2026, three months to 2026-06-30$74.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001104659-26-094907.Report this figure
Diluted EPS$ per share(0.86)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.86 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-13, accession 0001558370-24-015530.Report this figurenot reported(0.69)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.69 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-14, accession 0001558370-25-007765.Report this figure(0.25)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-12, accession 0001558370-25-011235.Report this figure(0.15)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001104659-25-110383.Report this figurenot reported(0.20)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001104659-26-060333.Report this figure(0.45)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-12, accession 0001104659-26-094907.Report this figure(0.74)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.74 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001104659-25-110383.Report this figurenot reported(3.16)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$3.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001104659-26-060333.Report this figure(0.27)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-12, accession 0001104659-26-094907.Report this figure
Basic EPS$ per share(0.86)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.86 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-13, accession 0001558370-24-015530.Report this figurenot reported(0.69)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.69 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-14, accession 0001558370-25-007765.Report this figure0.25Basic EPS, Q2 FY2024, three months to 2024-06-30$0.25 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-12, accession 0001558370-25-011235.Report this figure(0.15)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.15 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-12, accession 0001104659-25-110383.Report this figurenot reported(0.18)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.18 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-13, accession 0001104659-26-060333.Report this figure(0.45)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-12, accession 0001104659-26-094907.Report this figure(0.74)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.74 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-12, accession 0001104659-25-110383.Report this figurenot reported(3.16)Basic EPS, Q1 FY2026, three months to 2026-03-31−$3.16 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-13, accession 0001104659-26-060333.Report this figure2.02Basic EPS, Q2 FY2026, three months to 2026-06-30$2.02 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-12, accession 0001104659-26-094907.Report this figure

Balance sheet

Cash and equivalents$24.0m, Q2 FY2026
Shareholders' equity−$231.2m, Q2 FY2026
Armata Pharmaceuticals, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m24.0Cash and equivalents, Q3 FY2023, at 2023-09-30$24.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-13, accession 0001558370-24-015530.Report this figure13.5Cash and equivalents, FY2023, at 2023-12-31$13.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-21, accession 0001558370-25-003406.Report this figure37.9Cash and equivalents, Q1 FY2024, at 2024-03-31$37.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-14, accession 0001558370-25-007765.Report this figure26.4Cash and equivalents, Q2 FY2024, at 2024-06-30$26.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-12, accession 0001558370-25-011235.Report this figure17.1Cash and equivalents, Q3 FY2024, at 2024-09-30$17.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-12, accession 0001104659-25-110383.Report this figure9.3Cash and equivalents, FY2024, at 2024-12-31$9.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-25, accession 0001104659-26-034532.Report this figure11.7Cash and equivalents, Q1 FY2025, at 2025-03-31$11.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-13, accession 0001104659-26-060333.Report this figure4.3Cash and equivalents, Q2 FY2025, at 2025-06-30$4.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-12, accession 0001104659-26-094907.Report this figure14.8Cash and equivalents, Q3 FY2025, at 2025-09-30$14.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-12, accession 0001104659-25-110383.Report this figure8.7Cash and equivalents, FY2025, at 2025-12-31$8.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-12, accession 0001104659-26-094907.Report this figure4.8Cash and equivalents, Q1 FY2026, at 2026-03-31$4.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-13, accession 0001104659-26-060333.Report this figure24.0Cash and equivalents, Q2 FY2026, at 2026-06-30$24.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-12, accession 0001104659-26-094907.Report this figure
Current assets$m36.6Current assets, Q3 FY2023, at 2023-09-30$36.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-14, accession 0001558370-23-019036.Report this figure19.2Current assets, FY2023, at 2023-12-31$19.2m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-21, accession 0001558370-25-003406.Report this figure41.7Current assets, Q1 FY2024, at 2024-03-31$41.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-07, accession 0001558370-24-007068.Report this figure30.9Current assets, Q2 FY2024, at 2024-06-30$30.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-13, accession 0001558370-24-012061.Report this figure22.4Current assets, Q3 FY2024, at 2024-09-30$22.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-13, accession 0001558370-24-015530.Report this figure11.3Current assets, FY2024, at 2024-12-31$11.3m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-25, accession 0001104659-26-034532.Report this figure13.2Current assets, Q1 FY2025, at 2025-03-31$13.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-14, accession 0001558370-25-007765.Report this figure7.5Current assets, Q2 FY2025, at 2025-06-30$7.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-12, accession 0001558370-25-011235.Report this figure16.9Current assets, Q3 FY2025, at 2025-09-30$16.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-12, accession 0001104659-25-110383.Report this figure10.7Current assets, FY2025, at 2025-12-31$10.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-12, accession 0001104659-26-094907.Report this figure5.9Current assets, Q1 FY2026, at 2026-03-31$5.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-13, accession 0001104659-26-060333.Report this figure27.2Current assets, Q2 FY2026, at 2026-06-30$27.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-12, accession 0001104659-26-094907.Report this figure
Total assets$m113Total assets, Q3 FY2023, at 2023-09-30$112.8m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-14, accession 0001558370-23-019036.Report this figure98.4Total assets, FY2023, at 2023-12-31$98.4m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-21, accession 0001558370-25-003406.Report this figure120Total assets, Q1 FY2024, at 2024-03-31$120.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-07, accession 0001558370-24-007068.Report this figure108Total assets, Q2 FY2024, at 2024-06-30$108.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-13, accession 0001558370-24-012061.Report this figure98.2Total assets, Q3 FY2024, at 2024-09-30$98.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-13, accession 0001558370-24-015530.Report this figure86.4Total assets, FY2024, at 2024-12-31$86.4m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-25, accession 0001104659-26-034532.Report this figure87.3Total assets, Q1 FY2025, at 2025-03-31$87.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-14, accession 0001558370-25-007765.Report this figure80.8Total assets, Q2 FY2025, at 2025-06-30$80.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-12, accession 0001558370-25-011235.Report this figure89.5Total assets, Q3 FY2025, at 2025-09-30$89.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-12, accession 0001104659-25-110383.Report this figure76.9Total assets, FY2025, at 2025-12-31$76.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-12, accession 0001104659-26-094907.Report this figure69.8Total assets, Q1 FY2026, at 2026-03-31$69.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-13, accession 0001104659-26-060333.Report this figure90.0Total assets, Q2 FY2026, at 2026-06-30$90.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-12, accession 0001104659-26-094907.Report this figure
Current liabilities$m21.9Current liabilities, Q3 FY2023, at 2023-09-30$21.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-14, accession 0001558370-23-019036.Report this figure16.5Current liabilities, FY2023, at 2023-12-31$16.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-21, accession 0001558370-25-003406.Report this figure110Current liabilities, Q1 FY2024, at 2024-03-31$110.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-07, accession 0001558370-24-007068.Report this figure123Current liabilities, Q2 FY2024, at 2024-06-30$123.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-13, accession 0001558370-24-012061.Report this figure118Current liabilities, Q3 FY2024, at 2024-09-30$118.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-13, accession 0001558370-24-015530.Report this figure48.2Current liabilities, FY2024, at 2024-12-31$48.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-25, accession 0001104659-26-034532.Report this figure111Current liabilities, Q1 FY2025, at 2025-03-31$110.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-14, accession 0001558370-25-007765.Report this figure120Current liabilities, Q2 FY2025, at 2025-06-30$120.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-12, accession 0001558370-25-011235.Report this figure140Current liabilities, Q3 FY2025, at 2025-09-30$139.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-12, accession 0001104659-25-110383.Report this figure8.9Current liabilities, FY2025, at 2025-12-31$8.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-12, accession 0001104659-26-094907.Report this figure9.2Current liabilities, Q1 FY2026, at 2026-03-31$9.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-13, accession 0001104659-26-060333.Report this figure250Current liabilities, Q2 FY2026, at 2026-06-30$250.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-12, accession 0001104659-26-094907.Report this figure
Total liabilities$m125Total liabilities, Q3 FY2023, at 2023-09-30$125.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-14, accession 0001558370-23-019036.Report this figure130Total liabilities, FY2023, at 2023-12-31$130.4m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-21, accession 0001558370-25-003406.Report this figure177Total liabilities, Q1 FY2024, at 2024-03-31$176.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-07, accession 0001558370-24-007068.Report this figure154Total liabilities, Q2 FY2024, at 2024-06-30$154.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-13, accession 0001558370-24-012061.Report this figure149Total liabilities, Q3 FY2024, at 2024-09-30$149.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-13, accession 0001558370-24-015530.Report this figure134Total liabilities, FY2024, at 2024-12-31$134.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-25, accession 0001104659-26-034532.Report this figure141Total liabilities, Q1 FY2025, at 2025-03-31$141.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-14, accession 0001558370-25-007765.Report this figure150Total liabilities, Q2 FY2025, at 2025-06-30$150.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-12, accession 0001558370-25-011235.Report this figure185Total liabilities, Q3 FY2025, at 2025-09-30$185.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-12, accession 0001104659-25-110383.Report this figure295Total liabilities, FY2025, at 2025-12-31$295.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-12, accession 0001104659-26-094907.Report this figure381Total liabilities, Q1 FY2026, at 2026-03-31$381.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-13, accession 0001104659-26-060333.Report this figure321Total liabilities, Q2 FY2026, at 2026-06-30$321.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-12, accession 0001104659-26-094907.Report this figure
Shareholders' equity$m(12.4)Shareholders' equity, Q3 FY2023, at 2023-09-30−$12.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-13, accession 0001558370-24-015530.Report this figure(32.1)Shareholders' equity, FY2023, at 2023-12-31−$32.1m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-25, accession 0001104659-26-034532.Report this figure(56.5)Shareholders' equity, Q1 FY2024, at 2024-03-31−$56.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-12, accession 0001558370-25-011235.Report this figure(46.1)Shareholders' equity, Q2 FY2024, at 2024-06-30−$46.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001104659-25-110383.Report this figure(51.0)Shareholders' equity, Q3 FY2024, at 2024-09-30−$51.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001104659-25-110383.Report this figure(48.0)Shareholders' equity, FY2024, at 2024-12-31−$48.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001104659-26-094907.Report this figure(53.8)Shareholders' equity, Q1 FY2025, at 2025-03-31−$53.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001104659-26-094907.Report this figure(69.5)Shareholders' equity, Q2 FY2025, at 2025-06-30−$69.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001104659-26-094907.Report this figure(95.6)Shareholders' equity, Q3 FY2025, at 2025-09-30−$95.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001104659-25-110383.Report this figure(219)Shareholders' equity, FY2025, at 2025-12-31−$218.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001104659-26-094907.Report this figure(312)Shareholders' equity, Q1 FY2026, at 2026-03-31−$311.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001104659-26-094907.Report this figure(231)Shareholders' equity, Q2 FY2026, at 2026-06-30−$231.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001104659-26-094907.Report this figure

Cash flow

Operating cash flow−$8.7m, Q2 FY2026
Capital expenditure$17.0k, Q2 FY2026
Armata Pharmaceuticals, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(9.7)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$9.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-13, accession 0001558370-24-015530. Derived: 9-month figure less the 6-month figure.Report this figure(8.1)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$8.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-21, accession 0001558370-25-003406. Derived: 12-month figure less the 9-month figure.Report this figure(10.6)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$10.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-14, accession 0001558370-25-007765.Report this figure(10.2)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$10.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-12, accession 0001558370-25-011235. Derived: 6-month figure less the 3-month figure.Report this figure(8.9)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$8.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001104659-25-110383. Derived: 9-month figure less the 6-month figure.Report this figure(7.9)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$7.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-25, accession 0001104659-26-034532. Derived: 12-month figure less the 9-month figure.Report this figure(7.6)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$7.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001104659-26-060333.Report this figure(7.2)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$7.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-12, accession 0001104659-26-094907. Derived: 6-month figure less the 3-month figure.Report this figure(4.3)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$4.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001104659-25-110383. Derived: 9-month figure less the 6-month figure.Report this figure(6.7)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$6.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-25, accession 0001104659-26-034532. Derived: 12-month figure less the 9-month figure.Report this figure(5.8)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$5.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001104659-26-060333.Report this figure(8.7)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$8.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-12, accession 0001104659-26-094907. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m3.5Capital expenditure, Q3 FY2023, three months to 2023-09-30$3.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-13, accession 0001558370-24-015530. Derived: 9-month figure less the 6-month figure.Report this figure2.4Capital expenditure, Q4 FY2023, three months to 2023-12-31$2.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-21, accession 0001558370-25-003406. Derived: 12-month figure less the 9-month figure.Report this figure0.3Capital expenditure, Q1 FY2024, three months to 2024-03-31$250.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-14, accession 0001558370-25-007765.Report this figure1.4Capital expenditure, Q2 FY2024, three months to 2024-06-30$1.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-12, accession 0001558370-25-011235. Derived: 6-month figure less the 3-month figure.Report this figure0.3Capital expenditure, Q3 FY2024, three months to 2024-09-30$340.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-12, accession 0001104659-25-110383. Derived: 9-month figure less the 6-month figure.Report this figure(0.1)Capital expenditure, Q4 FY2024, three months to 2024-12-31−$77.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-25, accession 0001104659-26-034532. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2025, three months to 2025-03-31$99.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-13, accession 0001104659-26-060333.Report this figure0.1Capital expenditure, Q2 FY2025, three months to 2025-06-30$149.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-12, accession 0001104659-26-094907. Derived: 6-month figure less the 3-month figure.Report this figure0.2Capital expenditure, Q3 FY2025, three months to 2025-09-30$242.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-12, accession 0001104659-25-110383. Derived: 9-month figure less the 6-month figure.Report this figure0.1Capital expenditure, Q4 FY2025, three months to 2025-12-31$52.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-25, accession 0001104659-26-034532. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2026, three months to 2026-03-31$63.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-13, accession 0001104659-26-060333.Report this figure0.0Capital expenditure, Q2 FY2026, three months to 2026-06-30$17.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-12, accession 0001104659-26-094907. Derived: 6-month figure less the 3-month figure.Report this figure
Dividends paid$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)62.04m, Q2 FY2026
Armata Pharmaceuticals, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares36.0Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3036,038,686 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-14, accession 0001558370-23-019036.Report this figure36.0Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3136,045,040 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-07, accession 0001558370-24-007068.Report this figure56.5Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3056,544,698 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-13, accession 0001558370-24-012061.Report this figure36.1Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3036,086,990 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-13, accession 0001558370-24-015530.Report this figure36.1Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3136,124,980 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-14, accession 0001558370-25-007765.Report this figure58.2Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3058,246,626 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-12, accession 0001558370-25-011235.Report this figure36.2Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3036,180,124 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-12, accession 0001104659-25-110383.Report this figure59.5Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3159,478,662 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-13, accession 0001104659-26-060333.Report this figure36.2Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3036,193,479 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-12, accession 0001104659-26-094907.Report this figure36.2Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3036,226,285 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-12, accession 0001104659-25-110383.Report this figure36.5Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3136,530,284 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-13, accession 0001104659-26-060333.Report this figure62.0Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3062,041,700 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-12, accession 0001104659-26-094907.Report this figure

Shares outstanding: 37.18mShares outstanding, period not labelled, at 2026-08-0637,181,979 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-12, accession 0001104659-26-094907.Report this figure at Aug 6, 2026, from the cover of the 10-Q filed Aug 12, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:28 ET. Listed shows no prices and gives no investment advice.